Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI1814 in Mild to Moderate Alzheimer's Disease
NCT02036645Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2014
- Primary completion
- Sep 2016
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI1814 in Alzheimer's disease (AD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Tolerability as Measured by Participant Withdrawal for an Adverse Event at 7 months. Started Feb 2014; status: completed.
02
Drugs
MEDI1814
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02036645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036645.